Ketobemidone
Clinical data | |
---|---|
Trade names | Ketogan |
Other names | Ketobemidone, Cliradon, Cymidon, Ketogan, Ketorax |
AHFS/Drugs.com | International Drug Names |
Routes of administration | By mouth, rectal, intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 34~40% (oral), 44% (rectal) |
Elimination half-life | 2–4 hours |
Duration of action | 3–5 hours |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Ketobemidone, sold under the brand name Ketogan among others, is a powerful
History
Ketobemidone was first synthesized in 1942 by Eisleb and colleagues,[4] at the laboratory of I.G. Farbenindustrie at Hoechst during the Second World War. The first study of it in humans was published in 1946,[5] and it was introduced in clinical medicine shortly after. It was not in clinical use in the United States when the Controlled Substances Act 1970 was promulgated and was assigned to Schedule I with an ACSCN of 9628. As of 2013, no annual manufacturing quota was assigned by the DEA.[6]
Pharmacology
Experiments on former addicts indicated it was quite addictive and in high doses, compared to other opioids, may have increased abuse potential in former and current opioid addicts. While some effort was first suggested for drafting of a resolution urging governments to stop manufacture and use of ketobemidone,
Analgesia after 5-10
Metabolism
Ketobemidone is mainly metabolized by
Chemistry
Ketobemidone is 1-methyl-4-(3-hydroxyphenyl)-4-propionylpiperidine. It is usually available as the
Because of a strong vesicant nature of bis(2-chloroethyl)methylamine there are many other routes developed for obtaining ketobemidone. A route depicted below lays through first alkylating the same (3-methoxyphenyl)acetonitrile with 2-chloro-N,N-dimethylethylamine or 2-chloro-N-benzyl-N-methylethylamine.[12] Next, those amines are alkylated once again using a mixed 1-bromo-2-chloroethane, thus completing the piperidine ring and obtaining a quaternary ammonium salt, which can be dequaternized using thiophenol salt[13] (for N,N-dimethylammonium) or catalytic hydrogenation[14] (for both compounds) to a common 4-(3-methoxyphenyl)-4-cyano-1-methyl-pyperidine. The latter yields ketobemidone after Grignard reaction with ethylmagnesium bromide and ether cleavage.
See also
References
- ^ https://www.ema.europa.eu/documents/psusa/ketobemidone-list-nationally-authorised-medicinal-products-psusa/0001807/202005_en.pdf [bare URL PDF]
- ^ PMID 9783723.
- ^ Brayfield A, ed. (9 January 2017). "Ketobemidone Hydrochloride: Martindale: The Complete Drug Reference". MedicinesComplete. London, UK: Pharmaceutical Press. Retrieved 6 September 2017.
- ^ GB patent 609763, "Manufacture of piperidyl ketones", published 1948-10-06, assigned to Ciba Ltd.
- ^ US patent 2486796, Meischer, K.; Kaegi, H., "Esters of 1-alkyl-4-hydroxyphenyl-piperidil-4-ketones", issued 1949-11-01
- ^ "DEA Diversion Control Division". Archived from the original on 2017-05-14. Retrieved 2014-05-03.
- ^ "Development of Synthetic Narcotic Drugs". Bulletin on Narcotic Drugs. 1956 (1): 11–14. 1956. Retrieved 2012-07-05.
- )
- INCB. 2004. Archived from the original(PDF) on 2006-10-07. Retrieved 2006-09-07.
- PMID 6114838.
- ISBN 9780815518563.
- .
- .
- .
External links
- "Ketobemidone". Drug Information Portal. U.S. National Library of Medicine.